Four more bills aimed at changing the trajectory of U.S. prescription drug prices are on their way to the Senate floor. The Senate Judiciary Committee gave a thumbs up Thursday to three bills intended to stop anticompetitive shenanigans and one that charges the Federal Trade Commission (FTC) with studying the role of supply chain middlemen to determine whether they're the good guys or the bad guys when it comes to drug prices.